HomeMarket NewsInvestors Cheer as Viking Therapeutics Surges on Roche's Acquisition of Carmot

Investors Cheer as Viking Therapeutics Surges on Roche’s Acquisition of Carmot

Actionable Trade Ideas

always free

Bathroom scale, measuring tape and space for text on white wooden floor, top view. Weight loss concept

Liudmila Chernetska

A whirlwind of excitement swept through the stock market as clinical-stage biotech Viking Therapeutics (NASDAQ:VKTX) skyrocketed by 15% on Monday following the news of Roche (OTCQX:RHHBY) agreeing to acquire the peer obesity drugmaker, Carmot Therapeutics (CRMO), in a deal potentially worth up to $3.1 billion.

Viking (VKTX), much like its peer Carmot (CRMO), has a revolutionary dual GLP-1/GIP agonist drug candidate in development, offering a glimmer of hope in the battle against various metabolic disorders, including obesity.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.